Todd Catherine S, Deese Jennifer, Wang Meng, Hubacher David, Steiner Markus J, Otunga Sheila, Van Damme Lut
FHI 360, Durham, NC, USA.
FHI 360, Durham, NC, USA.
Contraception. 2015 Mar;91(3):248-52. doi: 10.1016/j.contraception.2014.10.008. Epub 2014 Oct 22.
The objective was to assess associations between tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) exposure and levonorgestrel (LNG) concentrations among Kenyan HIV prevention trial participants using Sino-implant (II) LNG implants for contraception.
Women were offered implants among other contraceptive methods, were randomized to daily TDF-FTC or placebo, and followed monthly up to 56weeks. Associations between TDF-FTC exposure and mean LNG values were analyzed with linear mixed models.
Of 739 women, 29 (3.9%) received implants with no incident pregnancies and one discontinuation. Mean LNG concentrations over 56weeks among 28 women contributing data ranged between 214.0 and 659.8pg/mL with no significant difference between TDF-FTC and placebo arms or between variable levels of TDF-FTC adherence.
Concomitant TDF-FTC use was not associated with a significant change in plasma LNG concentrations among women using Sino-implant (II) in the first year of use.
评估在肯尼亚使用中研Ⅱ型左炔诺孕酮(LNG)宫内节育器避孕的HIV预防试验参与者中,替诺福韦酯富马酸盐-恩曲他滨(TDF-FTC)暴露与左炔诺孕酮(LNG)浓度之间的关联。
为女性提供宫内节育器及其他避孕方法,将她们随机分为每日服用TDF-FTC组或安慰剂组,并随访56周,每月进行一次。采用线性混合模型分析TDF-FTC暴露与平均LNG值之间的关联。
739名女性中,29名(3.9%)接受了宫内节育器,无意外妊娠事件发生,1人停用。28名提供数据的女性在56周内的平均LNG浓度在214.0至659.8pg/mL之间,TDF-FTC组与安慰剂组之间或不同水平的TDF-FTC依从性之间无显著差异。
在使用中研Ⅱ型宫内节育器的女性中,第一年同时使用TDF-FTC与血浆LNG浓度的显著变化无关。